Manage Tickers Link Financial Account

Has my stock been accused of fraud?Join over 160k users who know.

Ticker	Price	Change($)	Change(%)	Shares	Volume	Prev Close	Open	Gain($)	Gain(%)

Ticker	Status	Jurisdiction	Filing Date	CP Start	CP End	CP Loss	Deadline

Ticker	Case Name	Status	CP Start	CP End	Deadline	Settlement Amt

Ticker	Name	Date	Analyst Firm	Up/Down	Target ($)	Rating Change	Rating Current

Valneva's IXCHIQ Shows 95% Antibody Seroresponse Sustained Four Years After Single Dose In Adults Aged 18 To 65+

Author: Benzinga Newsdesk | September 30, 2025 12:25am

Long-lasting antibody persistence was comparable in older (65+) and younger adults
Long-term antibody persistence is a key competitive advantage for a vaccine targeting unpredictable outbreak diseases like chikungunya

Posted In: VALN